Latest / Startup Stories with Fexingo: Conversations About Founders, Funding, and Building Companies from Zero / How Hims and Hers Built a Direct to Consumer Health Empire
Transcript
- Lucas: If I told you five years ago that a company selling hair loss treatments, erectile dysfunction meds, and antidepressants through a trendy website would be worth over five billion dollars, you would have laughed. Well, that company is Hims and Hers, and it is now one of the fastest-growing telehealth platforms in the United States. Luna: It is wild how they normalized talking about stuff people usually avoid at dinner parties. And they did it without being clinical or gross. Lucas: Exactly. The founder, Andrew Dudum, understood that a huge part of healthcare is actually about psychology. People don't want to feel embarrassed when they need treatment. So he built a brand that feels more like a skincare startup than a pharmacy. The site uses pastel colors, clean product shots, and friendly language. No white coats, no sterile waiting rooms. Luna: But behind that friendly face is a very serious business. They went public in 2021 via a SPAC, and their revenue has been climbing fast. For 2025, they reported over one point two billion dollars in revenue. Lucas: Right. And what's interesting is how they got there. The model is simple on the surface. You go online, fill out a questionnaire, a licensed provider reviews it, and if appropriate, they prescribe a medication that gets shipped to your door. It's a subscription, usually around thirty to fifty dollars a month. But the secret sauce is the marketing. Luna: They basically turned Instagram and TikTok into their primary sales channel. They run ads that feel like native content, using humor and relatability. One of their early campaigns was literally a 'hair loss' meme. Lucas: And it worked because they weren't trying to sell to everyone. They targeted a specific pain point. Men in their twenties and thirties who were starting to notice thinning hair but didn't want to go to a dermatologist. The stigma was real. Hims made it feel like a lifestyle choice, not a medical condition. Luna: They also expanded into women's health under the 'Hers' brand, covering birth control, skincare, and mental health. That doubled their addressable market. Lucas: But here's where it gets tricky. Healthcare is heavily regulated. The FDA has rules about direct to consumer advertising, and the Federal Trade Commission watches for deceptive claims. Hims and Hers has faced several legal challenges. Luna: In 2024, they settled with the FTC over allegations that they had posted fake positive reviews for their products. They paid a fine but didn't admit wrongdoing. Lucas: That's a real blemish. But the bigger question is about the medical model itself. Are these consultations thorough enough? Some critics argue that the online questionnaires can miss critical health information. The company has protocols in place, but it's an ongoing debate. Luna: I see their side too though. They are expanding access. A lot of people don't have a primary care doctor. Telehealth can be a gateway to care they otherwise wouldn't get. Lucas: That's the classic disruptor tension. Lower barriers, but also potentially lower quality. Hims and Hers is walking that line every day. And they've been pretty transparent about their medical oversight. They employ licensed physicians and nurse practitioners in all fifty states. Luna: Let's talk about the numbers that caught my eye. Their gross margins are around seventy five percent. That's closer to a software company than a traditional pharmacy. Lucas: Because they own the supply chain. They source generic medications, repackage them under their brand, and ship directly. No middleman. They also have their own manufacturing and fulfillment facilities now, which brings costs down even further. Luna: It's a very capital-efficient model. They raised about two hundred million dollars before going public, which is moderate for a healthtech company. And they've been cash-flow positive for several quarters. Lucas: That's rare in the startup world. Most high-growth companies burn cash for years. Hims and Hers reached profitability faster because their customer acquisition costs are relatively low thanks to that viral marketing. Luna: Their customer lifetime value is also high because it's a subscription. Once someone signs up for hair loss treatment, they're likely to stay on it for months or years. Lucas: And they cross-sell. If you come in for hair loss, they'll offer you a multivitamin, a shampoo, maybe even a telehealth visit for something else. It's a classic product-led growth strategy, but in a regulated industry. Luna: One thing that stands out to me is how they've handled the mental health side. They offer therapy and psychiatry through Hers. That's a massive market, and they entered it carefully, with licensed therapists. Lucas: Mental health is a huge opportunity. The stigma around it is fading, and the pandemic accelerated that. Hims and Hers was well positioned because they already had the telehealth infrastructure and the brand trust. Luna: But competition is fierce. You've got Ro, Nurx, Lemonaid, and even big players like Amazon Pharmacy getting into the game. Lucas: Amazon is the elephant in the room. They have the logistics and the customer base. But they don't have the brand. Hims and Hers built a relationship with a specific demographic. That's hard to replicate. Luna: They also have a very strong content strategy. Their blog and social media don't just push products; they publish educational articles and personal stories. It builds trust. Lucas: Trust is the currency in healthcare. One bad experience can kill a brand. So far, Hims and Hers has managed to keep their customer satisfaction scores high, at least based on app store reviews. Luna: By the way, if you're getting value from these deep dives into how startups are reshaping industries, consider tossing a few dollars our way at buy me a coffee dot com slash fexingo. It genuinely helps us keep the show ad-free. Lucas: Yeah, even a couple of bucks a month makes a real difference. We're not backed by venture capital, just listeners like you. It's a small gesture that goes a long way. Luna: Alright, back to Hims and Hers. Let's look at their international expansion. They launched in the UK and Canada in 2024. That's a whole new regulatory landscape. Lucas: International is a logical next step, but it's not easy. Each country has its own drug approval process, privacy laws, and cultural norms. In the UK, they had to partner with local pharmacies to dispense medications. Luna: But the UK market is also less saturated. There aren't as many direct to consumer telehealth brands there. It could be a big growth driver. Lucas: They also started offering weight management medications, including GLP-1s like semaglutide. That market is exploding. Hims and Hers can tap into it with their existing subscription infrastructure. Luna: Weight loss is a huge opportunity, but also a risky one. The FDA has been scrutinizing compounded versions of these drugs. Hims and Hers uses compounding pharmacies for some of their offerings. Lucas: That's a regulatory tightrope. If the FDA cracks down, it could hurt their revenue. But they've also partnered with brand-name manufacturers to offer brand options. They're hedging. Luna: It's smart to have multiple sources. I think the key takeaway from Hims and Hers is that they proved you can build a serious healthcare company with a consumer brand approach. They made healthcare feel approachable. Lucas: And they did it by focusing on the user experience first. The medical part came second. That's a controversial stance, but it resonated with millions of people. The question now is whether they can maintain that balance as they scale. Luna: If they can keep the trust while navigating regulation, they could become the default online healthcare provider for a whole generation. Lucas: That's a big if. But watching them try is exactly why we cover startups. It's a real-time experiment in how to disrupt a heavily regulated industry with design and marketing. Luna: And the experiment is still unfolding. I'm curious to see how they handle the next five years. Lucas: Me too. And that's the story of Hims and Hers. Thanks for listening.